Почетна › Многи мијелом › Вашингтон
Kliničke studije za Многи мијелом u državi Вашингтон
30 studija za Многи мијелом traži učesnike na lokacijama u državi Вашингтон.
Gradovi u državi Вашингтон
Zvanični tekst studije (na engleskom)
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Fred Hutchinson Cancer Center - Seattle - Eastlake Avenue East /ID# 267940, Seattle
- Northwest Medical Specialties Tacoma /ID# 267117, Tacoma
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT05650632A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- VA Puget Sound Health Care System, Seattle
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT05137054A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- NorthWest Medical Specialties, PLLC, Tacoma
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT05552222Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Fred Hutchinson Cancer Center, Seattle
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT06433947Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
- Northwest Medical Specialties, PLLC, Tacoma
Тражи се учесникФаза 4
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT07609940A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Northwest Medical Specialties Tacoma /ID# 272506, Tacoma
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06953960Collection of Tissue Samples for Cancer Research
- Fred Hutchinson, Seattle
Тражи се учесникОпсервациона студија
2 Months · Оба пола · Ажурирано 27. 10. 2026. · NCT00900198Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Swedish Cancer Institute, Seattle
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT03761108A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- University of Washington, Seattle
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT04973605A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Northwest Medical Specialties, PLLC, Tacoma
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT05651932Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Fred Hutchinson Cancer Research Center, Seattle
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT07648264AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Edmonds
- Research Site, Seattle
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT05850234Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Fred Hutchinson Cancer Center, Seattle
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT06297226A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 103, Tacoma
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT07582432A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Puyallup
- Research Site, Seattle
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 29. 9. 2026. · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- NorthWest Medical Specialties, PLLC, Tacoma
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT07518186A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- University of Washington, Seattle
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT06500884A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Optum Care Washington, Everett
- American Oncology Network Vista Oncology Division / Physician partner associate, Olympia
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 24. 9. 2026. · NCT07477587TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Northwest Medical Specialties, Bonney Lake
- Northwest Medical Specialties, Federal Way
- Northwest Medical Specialties, Gig Harbor
- и још 4
Тражи се учесникФаза 2
Узраст 12 и старији · Оба пола · Ажурирано 22. 9. 2026. · NCT02693535Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT07181941Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Saint Joseph Medical Center Hematology and Oncology - Silverdale, Silverdale
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 19. 8. 2026. · NCT04566328Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Puyallup
- Research Site, Seattle
- Research Site, Seattle
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 14. 8. 2026. · NCT07764978Selinexor and Backbone Treatments of Multiple Myeloma Patients
- Fred Hutch Cancer Center, Seattle
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 15. 7. 2026. · NCT02343042Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Providence Regional Cancer System-Aberdeen, Aberdeen
- PeaceHealth Saint Joseph Medical Center, Bellingham
- Harrison Medical Center, Bremerton
- и још 15
Тражи се учесникФаза 3
Сви узрасти · Оба пола · Ажурирано 10. 6. 2026. · NCT05561387Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Swedish Medical Center - Seattle /ID# 268052, Seattle
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 5. 2026. · NCT06896916A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Puyallup
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 22. 4. 2026. · NCT06679101A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Swedish Medical Center, Seattle
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 18. 3. 2026. · NCT06153251PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
- University of Washington, Seattle
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 20. 4. 2025. · NCT05956457Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
- University of Washington, Seattle
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 11. 12. 2024. · NCT05053607Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
- All4Cure, Seattle
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 3. 5. 2024. · NCT06149910Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.